Napp announces authorisation of REZZAYO® (rezafungin) i

Napp announces authorisation of REZZAYO® (rezafungin) in Great Britain by the UK Medicines and Healthcare Products Regulatory Agency for the treatment of invasive candidiasis in adults¹

Napp announces authorisation of REZZAYO® (rezafungin) in Great Britain by the UK Medicines and Healthcare Products Regulatory Agency for the treatment of invasive candidiasis in adults¹

streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Related Keywords

Canada , United States , Cambridge , Cambridgeshire , United Kingdom , America , Great Britain , P Lewis White , Ben David , Asia Pacific , Antimicrob Chemother , Healthcare Products Regulatory Agency , Cardiff University Centre For Trials Research , Trademark Of Cidara Therapeutics Inc , Data Review Committee , Mycology Reference Laboratory , Napp Pharmaceuticals , Napp Pharmaceuticals Limited , Medical Media , Pharmaceuticals Limited , White Phd , Consultant Clinical Scientist , Reference Laboratory , Honorary Professor , Cardiff University Centre , Trials Research , Medical Director , Northern Europe , Orphan Drug Designation , Latin America , Cambridge Science Park , Milton Road , Registered Trademark , Cidara Therapeutics , Kingdom Medicines , Infect Dis , Rev Dis Primers , Englj Med , Database Syst Rev , Mundipharma Announce Positive Topline Results , Global Phase ,